HOXA10 and central nervous system cancer: It is noteworthy that HOXA10-AS serves as a prognostic glioma biomarker, and its high expression is associated with isocitrate dehydrogenase (IDH) mutations and neurodevelopmental pathway dysregulation (Isaev et al., 2021; Li et al., 2021b).